SS
PEAR

Steve Schonfeld’s Pear Therapeutics, Inc. Class A Common Stock PEAR Stock Holding History

Steve Schonfeld’s Portfolio PEAR Stock Details PEAR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-106,423
Closed -$1.06M – 2689
2021
Q3 		$1.06M Buy
106,423
+19,533
+22% +$193K 0.01% 930
2021
Q2 		$858K Buy
+86,890
New +$852K 0.01% 980

Other funds holding PEAR

Temasek Holdings
Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return
5VM
5AM Venture Management San Francisco, California $288M AUM 313.93% 1-Year Est. Return
SGA
SB Global Advisers London, United Kingdom $861M AUM 71.72% 1-Year Est. Return
AV
Arboretum Ventures Ann Arbor, Michigan $1.72M AUM 82.7% 1-Year Est. Return
TAA
TB Alternative Assets Grand Cayman, Cayman Islands $623M AUM 154.99% 1-Year Est. Return
PT
Palantir Technologies Aventura, Florida $9.72M AUM 6.46% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
AGM
Alpine Global Management New York $615M AUM 34.28% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SCM
Sarissa Capital Management Greenwich, Connecticut $178M AUM 118.43% 1-Year Est. Return

Steve Schonfeld's PEAR Position: Q4 2021 in Review

Steve Schonfeld sold out of Pear Therapeutics, Inc. Class A Common Stock (PEAR) in Q4 2021, closing a stake of 106,423 shares — an estimated $1.06M sold.

Steve Schonfeld first reported a position in PEAR in Q2 2021 and held it in 2 quarters. The position peaked at $1.06M in Q3 2021. 25 funds tracked by Wall St. Rank hold PEAR as of Q4 2021.

  • Steve Schonfeld reported no remaining Pear Therapeutics, Inc. Class A Common Stock position as of Q4 2021 after selling out during the quarter.
  • Steve Schonfeld sold 106,423 Pear Therapeutics, Inc. Class A Common Stock shares in Q4 2021, an estimated $1.06M.
  • Steve Schonfeld first reported a position in Pear Therapeutics, Inc. Class A Common Stock in Q2 2021 and held it in 2 quarters.
  • Steve Schonfeld's Pear Therapeutics, Inc. Class A Common Stock position peaked at $1.06M in Q3 2021.
  • 25 funds tracked by Wall St. Rank held Pear Therapeutics, Inc. Class A Common Stock as of Q4 2021.

Based on Schonfeld Strategic Advisors's 13F filing for Q4 2021, filed 14 Feb 2022.